Biologics process development establishes manufacturing processes designed to consistently deliver product of the required ...

The collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York.

SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance ...

Strategic long-term partnership with Alvotech to increase their global manufacturing capacity and support growth in demand ...

For biological drug substances, the effect of thawing and shear on product quality are evaluated. Fill interruption studies ...

OKLAHOMA CITY, July 15, 2026--(BUSINESS WIRE)--Cytovance Biologics, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

Stability problems can derail promising biologics late in development. Bringing high-throughput testing earlier into ...

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics, a U.S.-based Contract Development and Manufacturing Organization (CDMO), announced the launch of its in-house formulation development services, ...

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New YorkStrategic long-term ...

New upstream perfusion capabilities strengthen Cytovance’s ability to support next-generation biologics development with great flexibility, productivity, and process optimization Cytovance Biologics, ...

South Korea-based LOTTE Biologics, a contract development and manufacturing (CDMO) organisation, and Alvotech, a global biotechnology company specialising in the development and manufacture of ...